Maximova Natalia, Gregori Massimo, Boz Giulia, Simeone Roberto, Zanon Davide, Schillani Giulia, Zennaro Floriana
Bone Marrow Transplant Unit, Institute for Maternal and Child Health-IRCCS Burlo Garofolo, 34137 Trieste, Italy.
Department of Radiology, Institute for Maternal and Child Health-IRCCS Burlo Garofolo, 34137 Trieste, Italy.
Oncotarget. 2017 Jul 5;8(45):79650-79661. doi: 10.18632/oncotarget.19021. eCollection 2017 Oct 3.
The medical records of 44 pediatric patients who underwent allogeneic transplantation from 2011 to 2015 were retrospectively reviewed. Magnetic resonance imaging was used to measure iron concentrations in the liver, spleen, pancreas and bone. These patients were divided into two groups, 18 with non-elevated (< 100 μmol/g; Group 1) liver iron concentration before transplantation and 26 with elevated (> 100 μmol/g; Group 2) concentration . We compared transplant-related outcomes in the two groups. Iron overload was a negative prognostic risk factor for sinusoidal obstruction syndrome (OR = 17), osteoporosis (OR = 6.8), pancreatic insufficiency (OR = 17) and metabolic syndrome (OR = 15.1). No statistically significant differences in overall survival, disease-free survival, relapse incidence and incidence of acute or chronic graft-versus host disease were observed between the two groups. Mean times to engraftment of platelets (43.0 ± 35.3 days vs. 22.1 ± 9.5 days, < 0.05) and neutrophils (23.1 ± 10.4 days vs. 17.8 ± 4.6 days, < 0.05) appear significantly longer in Group 2 than in Group 1. Time to platelet engraftment showed statistically significant correlation with pre-transplant liver ( = 0.5775; < 0.001) and bone iron concentration ( = 0.7305; < 0.001). Post-transplant evaluation pointed out that iron concentration analyzed at the first follow-up peaked in all tissues. The iron accumulation was highest in bone, followed by the spleen, liver and pancreas. One year post transplant 9 of 18 (50%) patients in Group 1 and 6 of 22 (27%) in Group 2 presented with bone and/or spleen iron overload, but not with liver overload. Liver iron concentration is not always a reliable indicator of systemic siderosis or of the efficacy of chelation therapy.
回顾性分析了2011年至2015年间接受同种异体移植的44例儿科患者的病历。采用磁共振成像测量肝脏、脾脏、胰腺和骨骼中的铁浓度。这些患者被分为两组,18例移植前肝脏铁浓度未升高(<100μmol/g;第1组),26例移植前肝脏铁浓度升高(>100μmol/g;第2组)。我们比较了两组的移植相关结局。铁过载是窦性阻塞综合征(OR=17)、骨质疏松症(OR=6.8)、胰腺功能不全(OR=17)和代谢综合征(OR=15.1)的负面预后风险因素。两组在总生存期、无病生存期、复发率以及急性或慢性移植物抗宿主病发生率方面未观察到统计学上的显著差异。第2组血小板(43.0±35.3天vs.22.1±9.5天,<0.05)和中性粒细胞(23.1±10.4天vs.17.8±4.6天,<0.05)的平均植入时间明显长于第1组。血小板植入时间与移植前肝脏铁浓度(=0.5775;<0.001)和骨骼铁浓度(=0.7305;<0.001)呈统计学显著相关。移植后评估指出,首次随访时分析的所有组织中铁浓度均达到峰值。铁蓄积在骨骼中最高,其次是脾脏、肝脏和胰腺。移植后1年,第1组18例患者中有9例(50%)、第2组22例患者中有6例(27%)出现骨骼和/或脾脏铁过载,但未出现肝脏铁过载。肝脏铁浓度并不总是系统性铁过载或螯合治疗疗效的可靠指标。